Welcome to our dedicated page for Opgen SEC filings (Ticker: OPGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OpGen, Inc. (OPGN) SEC filings page on Stock Titan provides access to the company’s public reports and current reports filed with the U.S. Securities and Exchange Commission. These documents include Form 8‑K current reports describing material events, financing arrangements, and changes in executive leadership, along with other filings that detail OpGen’s financial condition, risk disclosures, and capital structure.
In its 8‑K filings, OpGen has reported entering into a Securities Purchase Agreement with AEI Capital Ltd., amendments to that agreement that expanded the potential aggregate amount of common stock that may be sold and extended the term, and a supplemental letter further extending the period during which the company may sell shares. These filings also explain that shares issued under the agreement are intended to be sold without registration in reliance on exemptions under the Securities Act and related regulations.
Other 8‑K filings disclose management and board changes, including resignations and appointments of executive officers such as the chief executive officer and president, and provide basic terms of related employment or promotion letters. Earlier financial filings referenced in OpGen’s news releases discuss its conclusion that there is substantial doubt about its ability to continue as a going concern and outline potential strategic alternatives the company is evaluating.
On Stock Titan, investors can review these filings in sequence and use AI‑powered summaries to understand the key points of each document. The platform highlights material agreements, equity issuance terms, leadership transitions, and risk language, helping readers interpret how OpGen’s regulatory disclosures relate to its stated focus on precision medicine, molecular diagnostics, and antimicrobial resistance.
OpGen, Inc. reported that it acquired Sun Investment Enterprises Limited, a British Virgin Islands holding company that owns Malaysian fintech iCapX Sdn. Bhd., on December 1, 2025. iCapX operates a cap table management platform and provides related corporate advisory services.
OpGen agreed to pay a purchase price of $12,278,703.08, to be satisfied through the issuance of 2,028,867 shares of its common stock at $6.052 per share to AEI Capital Ltd., its controlling stockholder and the seller. As a result of the transaction, iCapX became an indirect, wholly owned subsidiary of OpGen.
After the acquisition closed, iCapX completed advisory services for a privately held client, earning an advisory fee of $80,000 plus common stock equal to 1.4% of the client’s outstanding equity, which OpGen estimates to be worth approximately $14 million. The share sale agreement includes customary representations, warranties and covenants, and OpGen notes that actual value received from the client may differ from its estimates.
OpGen, Inc. extended its existing equity financing arrangement with AEI Capital Ltd. The company originally entered a Securities Purchase Agreement allowing it to sell shares of common stock with an aggregate value of up to $3.0 million, later amended to permit two additional tranches of $3.0 million each, for a total of $9.0 million, and to extend sales through December 31, 2025. A new Supplemental Letter dated December 17, 2025 further extends OpGen’s ability to sell common stock under this agreement until December 31, 2026. These shares may be sold without registration in reliance on Section 4(a)(2) of the Securities Act and Regulations D and S as sales to accredited investors and under similar state law exemptions.
Separately, on December 18, 2025, David Lazar notified OpGen of his resignation as President, effective January 8, 2026. His resignation is stated not to result from any disagreement regarding the company’s operations, policies, or practices.
OpGen, Inc. announced a leadership change with the resignation of John Tan Honjian as Chief Executive Officer, while he continues to serve as Chairman of the Board. The company appointed Christian-Laurent Bonte as the new Chief Executive Officer of both OpGen and its wholly owned subsidiary, CapForce International Holdings Ltd.
Mr. Bonte, age 49, brings extensive investment banking and capital markets experience from roles in Hong Kong and Singapore, including positions at Meyzer Capital Management, Far Cap Pte Ltd, and ARC Capital Ltd. Under his promotion letter with CapForce, he will receive an initial annual base salary of $156,000, a guaranteed minimum annual bonus of $13,000, a performance bonus ranging from $26,000 to $312,000, eligibility for per-deal incentive payments, and an annual stock grant targeted at $200,000 based on performance.
OpGen, Inc. has pivoted from infectious disease diagnostics to financial services and fintech through its CapForce subsidiary, which provides listing sponsorship and consulting services. For the nine months ended September 30, 2025, OpGen generated $4,000,000 of revenue from a single international listing sponsorship client, but reported no revenue in Q3 2025.
The company posted Q3 2025 net loss of $608,730, yet remained profitable year-to-date with $2,493,129 of net income, driven by the new business line and tight operating expenses. At September 30, 2025, OpGen held $414,211 in cash and cash equivalents, $302,262 of restricted cash, a $5,000,000 equity investment in the client, and $4,043,838 of accounts receivable tied to that same relationship, while stockholders’ equity increased to $10,157,965 from $7,380,628 at year-end 2024.
Liquidity relies heavily on a financing arrangement with controlling stockholder AEI Capital Ltd., under which OpGen may sell up to an additional $7,000,000 of common stock through December 31, 2025; management believes this, together with current cash, can fund operations for more than 12 months. The company’s common stock was delisted from Nasdaq following failure to meet the stockholders’ equity listing standard and now trades on the OTC Markets Pink Limited Market under the symbol OPGN, and the business is highly concentrated, with one customer representing 99% of accounts receivable and 100% of 2025 year-to-date revenue.
FAQ
What is the current stock price of Opgen (OPGN)?
What is the market cap of Opgen (OPGN)?
